Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics

Blood (2024) 143 (13): 1242–1258.

https://doi.org/10.1182/blood.2023021581

Published: 2024

Includes: Supplemental data

Journal Articles

CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma

Blood (2023) 142 (18): 1543–1555.

https://doi.org/10.1182/blood.2023020211

Published: 2023

Includes: Supplemental data

Journal Articles

Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma

Blood (2023) 142 (3): 260–273.

https://doi.org/10.1182/blood.2022019451

Published: 2023

Includes: Supplemental data

Journal Articles

TP53 CRISPR/Cas9 Reveals Strict BAX Dependence in the Response to BH3 Mimetic Targeting MCL1

Romane Durand, Domitille Costes-Tertrais, Geraldine Descamps, Christelle Dousset, Sophie Maïga, Jean-Baptiste Alberge, Elise Douillard, Jennifer Derrien, Celine Bellanger, David Chiron, Stephane Minvielle, Cyrille Touzeau, Philippe Moreau, Martine Amiot, Patricia Gomez-Bougie, Agnes Moreau-Aubry, Catherine Pellat-Deceunynck

Blood (2022) 140 (Supplement 1): 4198–4199.

https://doi.org/10.1182/blood-2022-155862

Published: 2022

Journal Articles

STP938, a Selective CTPS1 Inhibitor, Shows Single Agent Activity and Synergy with BCL2 Inhibition in Preclinical Models of Mantle Cell Lymphoma

David Chiron, Emmanuelle Menoret, Charlotte Kervoelen, Sophie Maïga, Celine Bellanger, Benoit Tessoulin, Cyrille Touzeau, Hélène Asnagli, Andy Parker, Philip Beer, Catherine Pellat-Deceunynck

Blood (2022) 140 (Supplement 1): 6014–6015.

https://doi.org/10.1182/blood-2022-159449

Published: 2022

Journal Articles

CARD11 and BCL2A1 Join Forces to Promote Resistance to Ibrutinib/Venetoclax Combination in Lymphoma Patients

Salomé Decombis, Celine Bellanger, Yannick Le Bris, Delphine Boulet, Jane Jardine, Christelle Dousset, Audrey Ménard, Charlotte Kervoelen, Elise Douillard, Philippe Moreau, Stephane Minvielle, Agnes Moreau-Aubry, Benoit Tessoulin, Nicolas Bidère, Steven Le Gouill, Catherine Pellat-Deceunynck, David Chiron

Blood (2022) 140 (Supplement 1): 2044–2045.

https://doi.org/10.1182/blood-2022-157694

Published: 2022

Journal Articles

The Novel Trifunctional Anti-BCMA NK Cell Engager SAR'514 Has Potent in-Vitro and in-Vivo Anti-Myeloma Effect through Dual NK Cell Engagement

Alexandre Tang, Laurent Gauthier, Jochen Beninga, Benjamin Rossi, Nicolas Gourdin, Audrey Blanchard-Alvarez, Céline Amara, Jacqueline Courta, Alexandra Basset, Dorothee Bourges, Alexandre Desjonqueres, Emmanuelle Menoret, Catherine Pellat-Deceunynck, Philippe Moreau, Yannis Morel, Marielle Chiron, Angela Virone-Oddos, Eric Vivier

Blood (2022) 140 (Supplement 1): 9985–9986.

https://doi.org/10.1182/blood-2022-166187

Published: 2022

Journal Articles

The IL32/BAFF Axis Supports Prosurvival Dialog in the Lymphoma Ecosystem and Is Disrupted By NIK Inhibition

Salome Decombis, Antonin Papin, Celine Bellanger, Clara Sortais, Christelle Dousset, Yannick Le Bris, Stephanie Blandin, Philippe Hulin, Benoit Tessoulin, Mathieu Rouel, Steven Le Gouill, Agnes Moreau-Aubry, Catherine Pellat-Deceunynck, David Chiron

Blood (2021) 138 (Supplement 1): 781.

https://doi.org/10.1182/blood-2021-144839

Published: 2021

Journal Articles

Inhibition of ATR Overcomes Chemotherapy Resistance in p53 Deficient Myeloma Cells

Louise Bouard, MDin training, Benoit Tessoulin, MD PhD, Géraldine Descamps, PhD, Cyrille Touzeau, MD PhD, Philippe Moreau, MD, Martine Amiot, PhD, Catherine Pellat-Deceunynck, PhD

Blood (2019) 134 (Supplement_1): 3109.

https://doi.org/10.1182/blood-2019-122547

Published: 2019

Journal Articles

BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment

Patricia Gomez-Bougie, Sophie Maiga, Benoît Tessoulin, Jessie Bourcier, Antoine Bonnet, Manuel S. Rodriguez, Steven Le Gouill, Cyrille Touzeau, Philippe Moreau, Catherine Pellat-Deceunynck, Martine Amiot

Blood (2018) 132 (25): 2656–2669.

https://doi.org/10.1182/blood-2018-03-836718

Published: 2018

Includes: Supplemental data

Journal Articles

CSF1R and BTK Inhibitions As Novel Strategies to Disrupt the Dialogue between Mantle Cell Lymphoma and Macrophages

Antonin Papin, Benoit Tessoulin, MD, Céline Bellanger, Anne Moreau, MD, Yannick LE Bris, MDPharmD, Herve Maisonneuve, MD, Philippe Moreau, Cyrille Touzeau, MD PhD, Martine Amiot, PhD, Catherine Pellat-Deceunynck, PhD, Steven Le Gouill, MD PhD, David Chiron, PhD

Blood (2018) 132 (Supplement 1): 2855.

https://doi.org/10.1182/blood-2018-99-114504

Published: 2018

Journal Articles

Poor Prognosis Associated with Gains of CCND1 in Mantle Cell Lymphoma Treated By First Line Immuno-Chemotherapy — a Study By the Lysa Group

Blood (2018) 132 (Supplement 1): 4099.

https://doi.org/10.1182/blood-2018-99-113303

Published: 2018

Journal Articles

Respective Place of Venetoclax and MCL1 BH3 Mimetics in Multiple Myeloma Treatment

Patricia Gomez-Bougie, PhD, Sophie Maïga, Benoit Tessoulin, MD, Jessie Bourcier, MD, Antoine Bonnet, MD, Géraldine Descamps, PhD, Carolane Seiller, Cyrille Touzeau, MD PhD, Philippe Moreau, Catherine Pellat-Deceunynck, PhD, Martine Amiot, PhD

Blood (2018) 132 (Supplement 1): 953.

https://doi.org/10.1182/blood-2018-99-109987

Published: 2018

Journal Articles

Correlations between p16 Protein Expression and Genomic Profile in Mantle Cell Lymphoma and Impact on Survival, a Lyma-Genomic Project Conducted on Behalf of the Lysa Group

Yannick LE Bris, MDPharmD, Danielle Canioni, MD, Barbara Burroni, MD, Anne Moreau, MD, Benoit Tessoulin, MD, Florence Magrangeas, PhD, Marie-Helene Delfau, MD, Catherine Thieblemont, MD, Lucie Oberic, MD, Krimo Bouabdallah, MD, Emmanuel Gyan, MD PhD, David Chiron, PhD, Catherine Pellat-deceunynck, PhD, Mary Callanan, PhD, Stephane Minvielle, PhD, Marie C Bene, PharmSci, PhD, Olivier Hermine, MD PhD, Steven Le Gouill, MD PhD

Blood (2018) 132 (Supplement 1): 2846.

https://doi.org/10.1182/blood-2018-99-113268

Published: 2018

Journal Articles

Human Myeloma Cell Lines Mutation Landscape: Toward a Rationale Use of Cell Lines to Assess Drug Efficacy Prediction in Myeloma

Benoit Tessoulin, MD, Agnes Moreau-Aubry, PhD, Alban Gaignard, PhD, Martine Amiot, PhD, Catherine Pellat-Deceunynck, PhD

Blood (2017) 130 (Supplement 1): 1770.

https://doi.org/10.1182/blood.V130.Suppl_1.1770.1770

Published: 2017

Journal Articles

The Use of a BH3 Mimetic Toolkit Reveals a Switch of Myeloma Patients Dependency from BCL2 at Diagnosis to MCL1 at Relapse

Antoine Bonnet, MD, Jessie Bourcier, MD, Patricia Gomez-Bougie, PhD, Sophie Maïga, Benoit Tessoulin, MD, Philippe Moreau, MDPhD, Steven Le Gouill, MDPhD, Catherine Pellat-Deceunynck, PhD, Cyrille Touzeau, MD PhD, Martine Amiot, PhD

Blood (2017) 130 (Supplement 1): 4383.

https://doi.org/10.1182/blood.V130.Suppl_1.4383.4383

Published: 2017

Journal Articles

Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma

David Chiron, Céline Bellanger, Antonin Papin, Benoit Tessoulin, Christelle Dousset, Sophie Maiga, Anne Moreau, Julie Esbelin, Valérie Trichet, Selina Chen-Kiang, Philippe Moreau, Cyrille Touzeau, Steven Le Gouill, Martine Amiot, Catherine Pellat-Deceunynck

Blood (2016) 128 (24): 2808–2818.

https://doi.org/10.1182/blood-2016-06-720490

Published: 2016

Includes: Supplemental data

Journal Articles

Lymphoid-like Environment, Which Promotes Proliferation and Induces Resistance to BH3-Mimetics, Is Counteracted By Obinutuzumab in MCL: Biological Rationale for the Oasis Clinical Trial

David Chiron, PhD, Celine Bellanger, Antonin Papin, Benoit Tessoulin, MD, Christelle Dousset, Sophie Maiga, Anne Moreau, MD, Julie Esbelin, MD, Valerie Trichet, PhD, Selina Chen-Kiang, PhD, Philippe Moreau, Cyrille Touzeau, MD, Steven Le Gouill, MD PhD, Martine Amiot, Catherine Pellat-Deceunynck, PhD

Blood (2016) 128 (22): 1096.

https://doi.org/10.1182/blood.V128.22.1096.1096

Published: 2016

Journal Articles

The Oncolytic Measles Virus Preferentially Infects p53 Abnormal Myeloma Cells

Anne Lok, MD, Geraldine Descamps, PhD, Benoit Tessoulin, MD, Philippe Moreau, Steven Le Gouill, MD PhD, Frederic Tangy, PhD, Martine Amiot, Catherine Pellat-Deceunynck, PhD

Blood (2016) 128 (22): 310.

https://doi.org/10.1182/blood.V128.22.310.310

Published: 2016

Journal Articles

PRIMA-1 Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

Benoît Tessoulin, Géraldine Descamps, Philippe Moreau, Sophie Maïga, Laurence Lodé, Catherine Godon, Séverine Marionneau-Lambot, Thibauld Oullier, Steven Le Gouill, Martine Amiot, Catherine Pellat-Deceunynck

Blood (2014) 124 (10): 1626–1636.

https://doi.org/10.1182/blood-2014-01-548800

Published: 2014

NARROW

A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics

CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma

Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma

TP53 CRISPR/Cas9 Reveals Strict BAX Dependence in the Response to BH3 Mimetic Targeting MCL1

STP938, a Selective CTPS1 Inhibitor, Shows Single Agent Activity and Synergy with BCL2 Inhibition in Preclinical Models of Mantle Cell Lymphoma

CARD11 and BCL2A1 Join Forces to Promote Resistance to Ibrutinib/Venetoclax Combination in Lymphoma Patients

The Novel Trifunctional Anti-BCMA NK Cell Engager SAR'514 Has Potent in-Vitro and in-Vivo Anti-Myeloma Effect through Dual NK Cell Engagement

The IL32/BAFF Axis Supports Prosurvival Dialog in the Lymphoma Ecosystem and Is Disrupted By NIK Inhibition

Inhibition of ATR Overcomes Chemotherapy Resistance in p53 Deficient Myeloma Cells

BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment

CSF1R and BTK Inhibitions As Novel Strategies to Disrupt the Dialogue between Mantle Cell Lymphoma and Macrophages

Poor Prognosis Associated with Gains of CCND1 in Mantle Cell Lymphoma Treated By First Line Immuno-Chemotherapy — a Study By the Lysa Group

Respective Place of Venetoclax and MCL1 BH3 Mimetics in Multiple Myeloma Treatment

Correlations between p16 Protein Expression and Genomic Profile in Mantle Cell Lymphoma and Impact on Survival, a Lyma-Genomic Project Conducted on Behalf of the Lysa Group

Human Myeloma Cell Lines Mutation Landscape: Toward a Rationale Use of Cell Lines to Assess Drug Efficacy Prediction in Myeloma

The Use of a BH3 Mimetic Toolkit Reveals a Switch of Myeloma Patients Dependency from BCL2 at Diagnosis to MCL1 at Relapse

Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma

Lymphoid-like Environment, Which Promotes Proliferation and Induces Resistance to BH3-Mimetics, Is Counteracted By Obinutuzumab in MCL: Biological Rationale for the Oasis Clinical Trial

The Oncolytic Measles Virus Preferentially Infects p53 Abnormal Myeloma Cells

PRIMA-1 Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only